KAICO Powder for Pig, a Functional Feed Additive, Accelerates Expansion Across Asia Following Vietnam
Launch of Field Trials in Thailand and Strategic Partnership for Commercialization in Taiwan
KAICO Ltd. (Headquarters: Fukuoka, Japan; CEO: Kenta Yamato; hereafter “KAICO”) announces the further acceleration of its global expansion for its proprietary feed additive for pigs, KAICO Powder for Pig (hereafter “KAICO Powder”).
As part of this initiative, KAICO has commenced field trials at the farm of AMCOVET, a leading livestock company based in Bangkok, Thailand. In addition, KAICO has entered into a partnership agreement with Reber Genetics, a Taiwan-based animal pharmaceutical company headquartered in Taipei, to promote the distribution and commercialization of KAICO Powder in Taiwan.
KAICO Powder: A Next-Generation Feed Additive Simply Mixed into Feed
KAICO Powder is an orally administered, next-generation feed additive utilizing proteins produced through KAICO’s proprietary silkworm-based expression technology.
The key features of KAICO Powder are as follows:
- High Convenience:
The product can be stored and distributed at ambient temperature, requiring no specialized equipment. - Significant Reduction in Labor Burden:
By simply mixing it into feed, farmers can support animal health with minimal effort. Field results in Vietnam demonstrated up to a 99% reduction in administration time compared to conventional methods. - Reduced Stress on Animals:
Unlike traditional administration methods, KAICO Powder avoids physical stress on pigs, contributing to improved productivity and feeding efficiency.
KAICO Powder has already been registered as a feed additive by the Ministry of Agriculture and Rural Development in Vietnam in September 2024.
Key Initiatives in Thailand and Taiwan
- Field Trials at AMCOVET Farm in Thailand (Starting March 2026)
A field study involving approximately 300 pigs is underway to evaluate the product’s applicability under Thai farming conditions, as well as the practicality of its administration method. Based on the results, KAICO will assess further business expansion within the year. - Strategic Partnership with Reber Genetics in Taiwan
To enter the Taiwanese market, KAICO will collaborate with Reber on product registration, local validation, and the establishment of future distribution and sales channels.
Sunny Kang, Chairman of Reber (Right)
Social Impact and Future Outlook
The adoption of KAICO Powder is expected to significantly alleviate labor shortages in livestock farming while supporting stable and efficient animal production.
KAICO will continue to leverage its core silkworm-based protein expression technology to expand its product pipeline across various animal species and disease targets. Through these efforts, KAICO aims to contribute to global public health by protecting both humans and animals from health risks.
About KAICO
Driven by its mission, “Changing the world with silkworms,” KAICO is a biotechnology startup founded in April 2018 as a spin-out from Kyushu University.
The company focuses on developing pharmaceuticals, diagnostics, and research reagents targeting difficult-to-express proteins, utilizing its proprietary technology to produce recombinant proteins within silkworms. KAICO collaborates with pharmaceutical partners to advance innovative drug development.
KAICO is also actively developing oral vaccines for both humans and animals using silkworm-derived protein antigens and has filed patents related to this technology.